Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 9.01 · 8-K

TransCode Therapeutics, Inc.

RNAZNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director On September 10, 2026, TransCode Therapeutics, Inc. (the “Company”) announced that Thomas A. Fitzgerald, M.B.A.…

Filed Sep 11, 2026Accepted Sep 11, 2026, 5:00 PM EDTCIK 1829635Accession 0001104659-26-107115
Share

Company context

TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers We possess a diversified pipeline of therapeutic candidates, including two clinical stage assets, TTX-MC138, an antisense inhibitor of an oncogenic microRNA and Seviprotimut-L, a cancer vaccine. We also possess an oncolytic immunotherapy platform and three TTX-based pre-clinical stage assets.

Current securities

Recent company filings

  1. Other EventsOct 28, 2026
  2. Entry into a Material Definitive Agreement · Triggering Events That Accelerate or Increase a Direct Financial ObligationOct 1, 2026
  3. Other EventsSep 28, 2026
  4. 3 filingSep 21, 2026
  5. 10-Q filingAug 14, 2026

Registered securities in this filing

TRANSCODE THERAPEUTICS, INC. · 8-K · Filed 2026-09-11

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
RNAZ
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-09-09

Dimensions: Not supplied

Accession 000110465926107115 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director On September 10, 2026, TransCode Therapeutics, Inc. (the “Company”) announced that Thomas A. Fitzgerald, M.B.A. had resigned as Chief Financial Officer, principal financial officer and principal accounting officer of the Company, and as a member of the Board of Directors of the Company (the “Board”), as well as from all other officer and director positions he held with the Company and any of its subsidiaries, in each case effective as of September 9, 2026 (the “Separation Date”). Mr. Fitzgerald’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. In connection with Mr. Fitzgerald’s resignation, Mr. Fitzgerald and the Company entered into a Separation and Transition Services Agreement (the “Separation Agreement”), pursuant to which the Company agreed to pay Mr. Fitzgerald severance payments totaling up to $1,250,000, which consists of (i) a lump sum cash payment of $416,666.67 payable within 10 days following the effective date as defined in the Separation Agreement (the “Effective Date”), (ii) an aggregate of $416,666.67 payable in equal monthly installments over the 12-month period following the Effective Date (the “Severance Period”) and (iii) up to an additional $416,666.67 (the “Third Payment”), subject to the funding-related conditions described below. The Third Payment will be paid as follows: (i) if neither funding threshold described below is achieved before the first anniversary of the Effective Date (the “Anniversary”), the full Third Payment will be paid following the Anniversary; (ii) if the Company receives at least $5.0 million of Qualified Funding (as described below) before the Anniversary, the Company will pay 50% of the Third Payment and 50% of the then-unpaid monthly severance installments; (iii) if the Company receives at least $10.0 million of Qualified Funding before the Anniversary without previously achieving the $5.0 million threshold, the Company will pay the full Third Payment and all then-unpaid monthly severance installments; and (iv) if the Company achieves the $10.0 million threshold before the Anniversary after previously achieving the $5.0 million threshold, the Company will pay the remaining 50% of the Third Payment and all then-unpaid monthly severance installments. “Qualified Funding” generally includes gross funding received by the Company from any source. The Separation Agreement also provides that, as of the Effective Date, subject to Mr. Fitzgerald’s compliance with the Separation Agreement, all outstanding equity awards held by Mr. Fitzgerald will become fully vested and the exercise period for any such equity awards will be extended through the end of the original full term of such awards. In addition, the Separation Agreement provides that the Company will grant to Mr. Fitzgerald on the Separation Date an option to purchase 185,000 shares of the Company’s common stock at an exercise price equal to the closing price of the common stock on that date. The option will vest and become exercisable in equal monthly installments over the 12 months following the Separation Date, subject to 50% acceleration upon achievement of the $5.0 million funding threshold and full acceleration upon achievement of the $10.0 million funding threshold or the occurrence of a sale event. The Company will also pay Mr. Fitzgerald’s COBRA premiums for up to 12 months following the Separation Date, subject to earlier termination if Mr. Fitzgerald becomes eligible for health coverage from a subsequent employer or ceases to be eligible for COBRA coverage. If Mr. Fitzgerald does not elect or is not eligible for COBRA coverage, the Company will instead pay Mr. Fitzgerald’s portion of his Medicare premiums. During the Severance Period, Mr. Fitzgerald has agreed to provide up to 20 hours of transitional services during September 2026 without additional compensation, and may provide additional mutually agreed transitional services thereafter at an hourly rate. The Company and Mr. Fitzgerald also entered into a mutual release of claims, subject to certain exceptions. The foregoing description of the terms of the Separation Agreement is not complete and is qualified in its entirety by reference to the Separation Agreement, a copy of which is attached hereto as Exhibit 10.1. Appointment of Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer John Tattory was appointed to serve as the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, effective as of September 9, 2026. Beginning September 9, 2026, Mr. Tattory will provide his services as a consultant through Stout Risius Ross, LLC (“Stout”) at an agreed upon hourly rate. Mr. Tattory, aged 61, has extensive financial and operational leadership experience in private and publicly traded pharmaceutical, medical device, and biotechnology companies. He currently serves as a Managing Director at Stout, a global advisory firm. Prior to joining Stout, Mr. Tattory was at LS Associates providing CFO consulting services to public and private biotechnology and medical device companies. Prior to that, he held full-time CFO positions at Windtree Therapeutics, Inc., a once-publicly traded development stage biotechnology company, and Cerapedics, Inc., a privately held, commercial stage medical device company. He also previously held financial management positions at Bristol-Myers Squibb and Ernst & Young. Mr. Tattory is a certified public accountant (currently inactive status) and holds a B.S. degree in Commerce from Rider University. There is no arrangement or understanding between Mr. Tattory and any other person pursuant to which he was selected as an officer of the Company, and there are no family relationships between Mr. Tattory and any of the Company’s directors or executive officers. There are no transactions to which the Company is a party and in which Mr. Tattory has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description Number ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 10.1 Separation Agreement, effective as of September 9, 2026, by and between TransCode Therapeutics, Inc. and Thomas A. Fitzgerald, M.B.A. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.